Alpha 2.0
Login Register
» Authors » Ute Richarz

Ute Richarz

Explore the profile of Ute Richarz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 257
Followers 0
Related Specialties
Psychiatry
Pharmacology
Neurology
Top 10 Co-Authors
Adam Jacobs
R Karl Knight
Joris Vandenbossche
Sandra Waechter
Srihari Gopal
Peter Hu
Gaetano Morelli
Jayalakshmi Natarajan
Olav Bjorneboe
Dean Najarian
Published In
Pain Pract
Neuropsychiatr Dis Treat
Curr Med Res Opin
J Clin Pharmacol
Springerplus
Affiliations
Soon will be listed here.
Recent Articles
1.
Association between prolactin increasing antipsychotic use and the risk of breast cancer: a retrospective observational cohort study in a United States Medicaid population
Kern D, Shoaibi A, Shearer D, Richarz U, Killion L, Knight R
Front Oncol . 2024 Apr; 14:1356640. PMID: 38595824
Introduction: Results of retrospective studies examining the relationship between prolactin increasing antipsychotics and incident breast cancer have been inconsistent. This study assessed the association between use of high prolactin increasing...
2.
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
Turkoz I, Wong J, Chee B, Siddiqui U, Knight R, Richarz U, et al.
Ther Adv Psychopharmacol . 2023 Oct; 13:20451253231200258. PMID: 37786804
Background: The paliperidone palmitate 6-month (PP6M) long-acting injectable formulation is currently the longest dosing interval available for schizophrenia treatment. Objective: To compare treatment outcomes between a real-world external comparator arm...
3.
Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study
Richarz U, Han J, Bai Y, Chen E, Chung Y, Jhanwar V, et al.
Medicine (Baltimore) . 2023 Sep; 102(34):e34623. PMID: 37653768
Background: Evaluate efficacy and safety of paliperidone palmitate 6-monthly (PP6M) for patients with schizophrenia in the Asian subgroup of a global, multicenter, noninferiority phase-3 study (NCT03345342). Methods: Patients received paliperidone...
4.
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
Najarian D, Turkoz I, Knight R, Galderisi S, Lamaison H, Zalitacz P, et al.
Int J Neuropsychopharmacol . 2023 Jul; 26(8):537-544. PMID: 37480362
Background: Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term...
5.
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
Giron-Hernandez C, Han J, Alberio R, Singh A, Garcia-Portilla M, Pompili M, et al.
Neuropsychiatr Dis Treat . 2023 Apr; 19:895-906. PMID: 37077705
Purpose: To examine efficacy and safety of paliperidone palmitate (PP) 6-month (PP6M) vs PP3-month (PP3M) long acting injectable (LAI) in patients with schizophrenia from European sites previously stabilized on PP3M...
6.
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel P, et al.
Neuropsychiatr Dis Treat . 2023 Mar; 19:531-545. PMID: 36915909
Medication nonadherence in schizophrenia can have serious implications including relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer administrations, while ensuring sustained medication coverage. In this review, we summarize the...
7.
Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data
Conover M, Weaver J, Fan B, Leitz G, Richarz U, Li Q, et al.
Prostate . 2023 Mar; 83(7):729-739. PMID: 36879362
Background: Cardiovascular conditions are the most prevalent comorbidity among patients with prostate cancer, regardless of treatment. Additionally, cardiovascular risk has been shown to increase following exposure to certain treatments for...
8.
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study
Baciarello G, Ozguroglu M, Mundle S, Leitz G, Richarz U, Hu P, et al.
Eur J Cancer . 2021 Dec; 162:56-64. PMID: 34953443
Background: A post-hoc analysis of the phase-3 LATITUDE study assessed the impact of abiraterone acetate plus prednisone (AA+P) on overall survival (OS) and radiographic progression-free survival (rPFS) in men with...
9.
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma
He J, Schmerold L, Rampelbergh R, Qiu L, Potluri R, Dasgupta A, et al.
Adv Ther . 2020 Nov; 38(1):640-659. PMID: 33211297
Introduction: The objective of this study was to describe the treatment patterns among patients with newly diagnosed multiple myeloma (MM) who had not received autologous stem cell transplantation (ASCT). It...
10.
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe
Fife D, Waller J, Kaplan S, Hu P, Phillips S, Oliveria S, et al.
Clin Drug Investig . 2019 Jul; 39(11):1057-1066. PMID: 31325111
Background And Objective: Risk-minimization measures (RMM), including label revisions were implemented in Europe for domperidone because of evidence of increased incidence of cardiac arrhythmia and sudden cardiac death. In accordance...